Peptide inhibition of human cytomegalovirus infection

Virology Journal

Volumn 8, Issue , 2011, Pages

  Melnik, Lilia I ^a   Garry, Robert F ^a   Morris, Cindy A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; SYNTHETIC PEPTIDE; VIRUS FUSION PROTEIN; ANTIVIRUS AGENT; GLYCOPROTEIN B, SIMPLEXVIRUS; PEPTIDE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONCENTRATION RESPONSE; CYTOMEGALOVIRUS INFECTION; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HYDROPHOBICITY; LIPID BILAYER; NONHUMAN; NUCLEOTIDE SEQUENCE; PREPUCE; RATING SCALE; VIRUS INHIBITION; CELL CULTURE; CELL SURVIVAL; CYTOMEGALOVIRUS; DRUG ANTAGONISM; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; VIROLOGY; VIRUS ENTRY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS;

ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; FIBROBLASTS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 79951794466     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-76     Document Type: Article

References (56)

1. Immunobiology of Human Cytomegalovirus: from Bench to Bedside. T Crough R Khanna, Clin Microbiol Rev 2009 22 1 76 98 10.1128/CMR.00034-08 19136435
2. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. A Kenneson MJ Cannon, Rev Med Virol 2007 17 253 276 10.1002/rmv.535 17579921 (Pubitemid 47066638)
3. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. S Stagno RF Pass G Cloud WJ Britt RE Henderson PD Walton DA Veren F Page CA Alford, JAMA 1986 256 1904 1908 10.1001/jama.256.14.1904 3020264
4. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. MK Gandhi R Khanna, Lancet Infect Dis 2004 4 725 738 10.1016/S1473-3099(04)01202-2 15567122 (Pubitemid 39574344)
5. A social marketing approach to building a behavioural intervention for congenital cytomegalovirus. SL Bate MJ Cannon, Health Promot Pract 2009 19515860
6. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. AY Yamamoto MM Mussi-Pinhata SB Boppana Z Novak VM Wagatsuma F Oliveira Pde G Duarte WJ Britt, Am J Obstet Gynecol 2010 202 3 297 305 10.1016/j.ajog.2009.11.018 20060091
7. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. AJ Davison A Dolan P Akter C Addison DJ Dargan DJ Alcendor DJ McGeoch GS Hayward, Anal Biochem 1987 162 156 159 2440339
8. Cytomegaloviruses. ES Mocarski Jr T Shank RF Pass, Fields Virology Philadelphia: Lippincott Williams & Wilkins, Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, 5 2007 2 2701 2772
9. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. SM Varnum DN Streblow ME Monroe P Smith KJ Auberry L Pasa-Tolic D Wang DG Camp K Rodland S Wiley W Britt T Shenk RD Smith JA Nelson, J Virol 2004 78 10960 10966 10.1128/JVI.78.20.10960-10966.2004 15452216 (Pubitemid 39299636)
10. Disulfide bond configuration of human cytomegalovirus glycoprotein B. M Lopper T Compton, J Virol 2002 76 6073 6082 10.1128/JVI.76.12.6073-6082.2002 12021340 (Pubitemid 34556302)
11. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. X Wang S-M Huong ML Chin N Raab-Traub ES Huang, Nature 2003 424 456 461 10.1038/nature01818 12879076 (Pubitemid 36917497)
12. Platelet-derived growth factor- receptor activation is required for human cytomegalovirus infection. L Soroceanu A Akhavan C Cobbs, Nature 2008 455 391 396 10.1038/nature07209 18701889
13. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. T Compton EA Kurt-Jones KW Boehme J Belko E Latz DT Golenbock RW Finberg, J Virol 2003 77 4588 4596 10.1128/JVI.77.8.4588-4596.2003 12663765 (Pubitemid 36402808)
14. Integrin v3 is a coreceptor for human cytomegalovirus. X Wang DY Huang SM Huong ES Huang, Nature Medicine 2005 11 515 521 10.1038/nm1236 15834425
15. Integrin-mediated migration of murine B82L fibroblasts is dependent on the expression of an intact epidermal growth factor receptor. J Li ML Lin GJ Wiepz AG Guadarrama PJ Bertics, J Biol Chem 1999 274 11209 11219 10.1074/jbc.274.16.11209 10196208
16. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. S Miyamoto H Teramoto JS Gutkind KM Yamada, J Cell Biol 1996 135 1633 1642 10.1083/jcb.135.6.1633 8978828 (Pubitemid 26427657)
17. Alphavbeta3 integrin associated with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. M Schneller K Vuori E Ruoslahti, EMBO 1997 16 5600 5607 10.1093/emboj/16.18.5600 (Pubitemid 27399852)
18. Structural domains involved in human cytomegalovirus glycoprotein B-mediated cell-cell fusion. S Bold M Ohkin W Garten K Radsak, J Gen Virol 1996 77 Pt 9 2297 2302 10.1099/0022-1317-77-9-2297 8811030 (Pubitemid 26316101)
19. Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment. S Keay B Baldwin, J Virol 1991 65 5124 5128 1651427
20. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. D Navarro P Paz S Tugizov K Topp J La Vail L Pereira, Virology 1993 197 143 158 10.1006/viro.1993.1575 7692667
21. Mutated forms of human cytomegalovirus glycoprotein B are impaired in inducing syncytium formation. S Tugizov Y Wang I Qadri D Navarro E Maidji L Pereira, Virology 1995 209 580 591 10.1006/viro.1995.1290 7778290
22. Differential effects of glycoprotein B epitope-specific antibodies on human cytomegalovirus-induced cell-cell fusion. D Gicklhorn M Eickmann G Meyer M Ohlin K Radsak, J Gen Virol 2003 84 1859 1862 10.1099/vir.0.19017-0 12810880 (Pubitemid 36805921)
23. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread, but not for virion attachment, assembly, or egress. MK Isaacson T Compton, J Virol 2009 83 3891 3903 10.1128/JVI.01251-08 19193805
24. Human cytomegalovirus cell tropism and pathogenesis. C Sinzger G Jahn, Intervirology 1996 39 302 319 9130041 (Pubitemid 27174134)
25. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. CA Stoddart RD Cardin JM Boname WC Manning GB Abenes ES Mocarski, J Virol 1994 68 6243 6253 8083964 (Pubitemid 24294874)
26. Drug targets in cytomegalovirus infection. G Andrei E De Clercq R Snoeck, Infectious disorders-drug targets 2009 9 2 201 222 19275707
27. Antiviral intervention, resistance and perspectives. D Michel T Mertens, Cytomegaloviruses Molecular biology and immunology Caister Academic Press, Reddehase M, 2006 573 590
28. Crystal structure of glycoprotein B from herpes simplex virus I. EE Heldwein H Lou FC Bender GH Cohen RJ Eisenberg SC Harrison, Science 2006 313 5784 217 220 10.1126/science.1126548 16840698 (Pubitemid 44066251)
29. Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. M Backovic R Longnecker TS Jardetzky, Proc Natl Sci USA 2009 106 8 2880 2885 10.1073/pnas.0810530106
30. Crystal structure of the low- pH form of the vesicular stomatitis virus glycoprotein G. S Roche S Bressanelli FA Rey Y Gaudin, Science 2006 313 5784 187 191 10.1126/science.1127683 16840692 (Pubitemid 44066243)
31. The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines. J Kadlec S Loureiro NGA Abrescia DI Stuart I Jones, Nat Struct Mol Biol 2008 15 1024 1030 10.1038/nsmb.1484 18776902
32. Proteomics computational analyses suggest that baculovirus GP64 superfamily proteins are class III penetrenes. EG Garry RF Garry, Virol J 2008 5 28 39 10.1186/1743-422X-5-28 18282283
33. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. MP Cranage T Kousarides AT Bankier S Satchwell K Weston P Tomlinson B Barrel H Nart SE Bell AC Minson GL Smith, EMBO 1986 5 3057 3063
34. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. S Roche FA Rey Y Gaudin S Bressanelli, Science 2007 315 5813 843 848 10.1126/science.1135710 17289996
35. Peptide inhibitors of dengue virus and west Nile virus infectivity. YM Hrobowski RF Garry SF Michael, Virol J 2006 2 49 59 10.1186/1743-422X-2-49
36. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. B Sainz Jr EC Mossel WR Gallaher WC Wimley CJ Peters RB Wilson RF Garry, Virus Research 2006 120 146 155 10.1016/j.virusres.2006.03.001 16616792 (Pubitemid 43947310)
37. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor. AIDS Alert 2003 18 6 78 79 12866478
38. Model of the pre-insertion region of the spike (S2) fusion glycoprotein of the human SARS coronavirus: implications for antiviral therapeutics. WR Gallaher RF Garry, http://www.virology.net/Articles/sars/s2model.html
39. Are fusion peptides really "sided" insertional helices? WR Gallaher JP Segrest E Hunter, Cell 1992 70 4 531 532 10.1016/0092-8674(92)90423- A 1505021
40. Peptides from conserved regions of paramoxovirus fusion (F) proteins are potent inhibitors of viral fusion. DM Lambert S Barney AL Lambert K Guthrie R Medinas DE Davis T Bucy J Erickson G Merutka SR Petteway Jr, Proc Natl Acad Sci USA 1996 93 5 2186 2191 10.1073/pnas.93.5.2186 8700906 (Pubitemid 26079903)
41. Oligopeptide inhibitors of HIV-induced syncytium formation. RJ Owens CC Tanner MJ Mulligan RV Srinivas RW Compans, AIDS Res Hum Retroviruses 1990 6 11 1289 1296 2078410
42. Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. NM Qureshi DH Coy RF Garry LA Henderson, AIDS 1990 4 6 553 5538 10.1097/00002030-199006000-00009 1974767
43. Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-terminal of the F1 or HA1 viral polypeptides. CD Richardson A Scheid PW Choppin, Virology 1980 105 1 205 222 10.1016/0042-6822(80)90168-3 7414950 (Pubitemid 10049375)
44. Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion. KA Silburn DA McPhee AL Maerz P Poumbourios RG Whittaker A Kirkpatrick WG Reilly MK Manthey CC Curtain, AIDS Res Hum Retroviruses 1998 14 5 385 392 10.1089/aid.1998.14.385 9546797 (Pubitemid 28125696)
45. Functional importance of the coiled-coil of the Ebola virus glycoprotein. S Watanabe A Takada T Watanabe H Ito H Kida Y Kawaoka, J Virol 2000 74 21 10194 10201 10.1128/JVI.74.21.10194-10201.2000 11024148
46. A synthetic peptide from HIV-1 gp31 is a potent inhibitor of virus-mediated cell-cell fusion. C Wild T Greenwell T Matthews, AIDS Res Hum Retroviruses 1993 9 11 1051 1053 10.1089/aid.1993.9.1051 8312047
47. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. C Wild T Oas C McDanal D Bolognesi T Matthews, Proc Nat Acad Sci USA 1992 89 21 10537 10541 10.1073/pnas.89.21.10537 1438243
48. Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions. JK Young D Li MC Abramowitz TG Morrison, J Virol 1999 73 7 5945 5956 10364347 (Pubitemid 29274882)
49. Experimentally determined hydrophobicity scale for proteins at membrane interfaces. WC Wimley SH White, Nat Struct Biol 1996 3 10 842 848 10.1038/nsb1096-842 8836100 (Pubitemid 26330634)
50. Multiple peptides homologous to Herpes Simplex Virus Type 1 glycoprotein B inhibit viral infection. R Akkarawongsa NE Pocaro G Case AW Kolb CR Brandt, Antimicrob Agents and Chemotherapy 2009 53 3 987 996 10.1128/AAC.00793-08
51. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. S Fisher O Genbacev E Maidji L Pereira, J Virol 2000 74 15 6808 6820 10.1128/JVI.74.15. 6808-6820.2000 10888620 (Pubitemid 30470664)
52. Placental evidence of cytomegalovirus infection of the fetus and neonate. M Mostoufi-zadeh SG Driscoll SA Biano RB Kundsin, Arch Pathol Lab Med 1984 108 5 403 406 6324716 (Pubitemid 14138107)
53. Could an infectious trigger explain the differential maternal response to shared placental pathology of preeclampsia and normotensive intrauterine growth restriction? P von Dadelszen LA Magee, Acta Obstet Gynecol Scand 2002 81 642 648 10.1034/j.1600-0412.2002.810710.x 12190839 (Pubitemid 34830401)
54. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. AS Istas GJ Demmler JD Dobbins JA Stewart, Clin Infect Dis 1995 20 3 665 670 7756493
55. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross placenta. P Brennan-Benson M Pakianathan P Rice S Bonora R Chakraborty M Charland, AIDS 2006 20 2 297 299 10.1097/01.aids. 0000200535.02232.1b 16511429
56. The PyMOL Molecular Graphics System. WL DeLano, 2002